On September 11, 2024, SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), announced a $50 million Series B funding round. The round was led by Johnson & Johnson Innovation - JJDC, Inc. and joined by S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, NovaVenture, and Heartwork Capital. Wilson Sonsini Goodrich & Rosati advised SpectraWAVE on the transaction.

The funding round will be used to advance commercial expansion and product additions to the company’s 510k-cleared HyperVue™ Imaging System. HyperVue is the first intravascular imaging technology to combine two important imaging technologies, DeepOCT and NIRS, while optimizing for image quality and procedural efficiency in the cath lab, including no-flush catheter prep, fast and long pullbacks designed to reduce and remove the use of contrast, and the most comprehensive AI-driven workflow and image analysis offering.

The Wilson Sonsini team that advised SpectraWAVE includes Jason Skolnik, Brandon Shaw, Trevor Dorne, and Stephanie Chen.

For more information, please see SpectraWAVE’s press release.